Decabid is developed by Eli Lilly.

What development phase is Decabid in?

Decabid is FDA-approved (marketed).

What is the generic name of Decabid?

INDECAINIDE is the generic (nonproprietary) name of Decabid.

Last reviewed 2026-04-20 · How we verify

Decabid (INDECAINIDE)

Eli Lilly · FDA-approved approved Small molecule Quality 15/100

At a glance

Generic name	INDECAINIDE
Sponsor	Eli Lilly
Target	Sodium channel protein type 5 subunit alpha
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved
First approval	1989

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Decabid CI brief — competitive landscape report
Decabid updates RSS · CI watch RSS
Eli Lilly portfolio CI